Consumer Healthcare Products Association Statement on Department of Justice’s Action on Supplements Claims Standards

Washington, D.C. (September 12, 2014) — The Consumer Healthcare Products Association (CHPA), the trade association representing the leading makers of over-the-counter (OTC) medicines and dietary supplements, released the following statement today in response to the United States Department of Justice’s (DOJ) decision to file a motion against Bayer for claims made in support of Phillips’ Colon Health.

“Without commenting on the specifics of this case, we are extremely concerned about the growing federal drift away from the longstanding legal standards for substantiating dietary supplement claims,” CHPA President and CEO Scott Melville said. “Specifically, we are alarmed about the increasingly rigid application of the principle of ‘competent and reliable scientific evidence’ and the undue emphasis on multiple controlled clinical trials for such non-pharmaceutical products.  We continue to believe that the public interest is best served when dietary supplement structure/function claims are supportable through a variety of rigorous and robust scientific studies, not simply randomized clinical trials.”

Contact Jenni Terry 202.429.9260


The Consumer Healthcare Products Association (CHPA) is the 133-year-old trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines and dietary supplements. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to promoting the increasingly vital role of over-the-counter medicines and dietary supplements in America’s healthcare system through science, education, and advocacy.